CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
Tazemetostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03009344
NCT03009344Phase 1Completed
CompareCT.gov

A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Eisai Co., Ltd.·interventional·Posted Jan 4, 2017·Updated Nov 10, 2022

In Brief

A Phase 1 clinical trial evaluating Tazemetostat for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. Completed, enrolled 7 participants across 2 sites.

Detailed Summary

This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 4, 2017
Enrollment StartJan 10, 2017
Primary CompletionJul 12, 2017
Study CompletionJun 17, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.5 years ago

Interventions

Tazemetostatdrug

Tazemetostat tablets.